Skip to content

Intraoperative and Post-operative Analgesic Effect of IV Acetaminophen for Sinus Surgery

A Double Blind, Randomized, Placebo-controlled Study to Investigate the Effectiveness of IV Acetominophen Administered During Functional Endoscopic Sinus Surgery in Reducing the Use of Opiates to Treat Postoperative Pain

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01608308
Acronym
IVAPAP
Enrollment
62
Registered
2012-05-31
Start date
2012-07-31
Completion date
2014-09-30
Last updated
2015-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Sinusitis

Keywords

Chronic Sinusitis, Pain Relief, Post-Operative Opioid Requirement, IV Acetaminophen, Functional Endoscopic Sinus Surgery, FESS

Brief summary

The purpose of this study is to assess the use of IV acetaminophen (Ofirmev) as a and safe and efficacious agent in reducing post-operative pain; we hypothesize that its use will reduce post-operative pain when compared to a control group using the visual analogue score (VAS) analog pain scoring system.

Detailed description

Unrelieved postoperative pain may result not only in suffering and discomfort, but may also lead to multiple physiological and psychological consequences which can contribute to adverse perioperative outcomes. Inadequate perioperative analgesia can potentially contribute to a higher incidence of myocardial ischemia. Additionally, the use of opioids has been associated with major side effects that can include impaired wound healing and delayed gastrointestinal (GI) motility that results in prolonged postoperative ileus. Intravenous acetyl-para-aminophenol (APAP, also known as acetaminophen) is considered as the non-opioid analgesic of choice to treat postoperative mild and moderate pain, and has been demonstrated in several randomized trials to be both safe and effective at reducing acute post-operative pain in both children and adults. Furthermore, in the treatment of severe pain, it can reduce the need for opioid-analgesics while exhibiting a relatively limited side effect profile when compared to opioids and nonsteroidal anti-inflammatory drugs. Chronic rhinosinusitis (CRS) describes a group of disorders characterized by inflammation of the nasal mucosa and/or paranasal sinuses for at least 12 consecutive weeks. In the United States, CRS affects approximately 30 million people, and represents 2% of the primary diagnoses in physician office visits, resulting in an estimated 200,000 sinus procedures annually. Patients suffering from CRS that is refractory to medical management complain of symptoms that include fatigue, headache, nasal drainage, facial pain and pressure, and decreased sense of smell. Functional endoscopic sinus surgery (FESS) represents a surgical approach to treating CRS that is unresponsive to medical management. Outcomes studies have identified FESS as efficacious at reducing the majority of symptoms related to CRS. Despite this, pain associated with CRS remains a significant co-morbidity that often is resistant to both medical and surgical management. Reducing the incidence and severity of acute post-operative pain is paramount to reducing the development of chronic pain that may exacerbate a patient's existing pain. The use of pre- and intra- operative IV acetaminophen thus serves as a unique pain management modality in this setting, as it has the potential for reducing post-operative complications and pain, with the additional benefit of minimal intraoperative bleeding, an undesirable complication often associated with FESS and with the use of non-steroidal anti-inflammatory drugs (NSAIDs). The use of IV acetaminophen in ear, nose, and throat (ENT) surgery is not a novel endeavor. Indeed, studies have demonstrated the efficacy and safety of IV acetaminophen for use in tonsillectomy and FESS. We wish to provide a more comprehensive analysis of pain management in the setting of FESS in the following ways : 1. by administering IV acetaminophen perioperatively (before start of surgery, and after surgery completion; 2. by employing a pain score of 4 (whereas other studies use 3) as a cutoff for breakthrough pain; and, 3. by addressing novel outcomes including patient sedation and patient satisfaction, in addition to opioid analgesic use. In our institution, we have completed a preliminary pilot study exploring the use of intravenous anesthesia which included acetaminophen during bilateral endoscopic sinus surgery. Secondary outcomes measured during the study included: 1. Pain 2. Rescue analgesic use 3. Nausea/Vomiting 4. Time spent in recovery 5. Successful discharge from the PACU and the Hospital Our pilot data has reaffirmed that the procedure is overall benign, with few associated risks and adverse events. Of note, none of the patients in our preliminary study required admission to the hospital after surgery for further observation as a result of uncontrolled pain or nausea. Based on this experience, we would like to explore the efficacy of intravenous acetaminophen (Ofirmev), a non opioid/non steroidal analgesic, in endoscopic sinus surgery.

Interventions

DRUGIV Acetaminophen

1000mg IV acetaminophen over 15 minutes every 4 hours for up to 2 doses.

DRUGPlacebo

100 mL of 0.9% normal saline over 15 minutes in place of IV acetaminophen.

Sponsors

Mallinckrodt
CollaboratorINDUSTRY
The University of Texas Health Science Center, Houston
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 68 Years
Healthy volunteers
No

Inclusion criteria

1. Patients undergoing surgical management for CRS (with or without polyps) 2. Operating time must be at least 2 hours in duration. 3. Number of sinuses involved must be 3 or greater

Exclusion criteria

1. History of hypersensitivity to acetaminophen 2. End stage renal disease 3. End stage liver disease 4. History of chronic pain, or use of opioid medication in the previous two weeks 5. Severe depression or anxiety 6. Use of gabapentin or any other pain modulator 7. History of acute sinusitis or mucocele 8. History of seizures 9. Known or suspected history of alcohol or drug abuse 10. Known or suspected history of morphine intolerance

Design outcomes

Primary

MeasureTime frameDescription
Pain Level Assessed Using a Visual Analogue Scale (VAS) Scale15 minutes and 120 minutes Post-OperativelyVAS is a validated, self-reported data sheet assessing average pain intensity. Possible scores range from 0 (no pain) to 10 (highest level of pain).

Secondary

MeasureTime frameDescription
Number of Participants Who Received Intraoperative Supplemental FentanylDuring Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)Number of participants who received intraoperative supplemental fentanyl. The decision to administer fentanyl is based on hemodynamic changes, such as increasing blood pressure and heart rate.
Number of Participants Who Experienced Postoperative Morbidity (Nausea)During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)Post-operative nausea will be monitored and measured through direct observation and nursing clinical record
Postoperative Vital Sign (Systolic Blood Pressure)During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery.
Total Doses of Postoperative Opiate (Morphine) UseDuring Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)The total amount of morphine utilized in Postoperative Acute Care Unit (PACU) will be recorded. One dose is a 1mg bolus of morphine.
Postoperative Vital Sign (Pulse)During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery.
Postoperative Vital Sign (Temperature)During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery.
Postoperative Vital Sign (Respiratory Rate)During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery.
Postoperative Vital Sign (Diastolic Blood Pressure)During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery.

Countries

United States

Participant flow

Recruitment details

Recruitment is completed.

Participants by arm

ArmCount
IV Acetaminophen
The experimental group will receive a preoperative dose of 1000mg IV acetaminophen over 15 minutes. This will occur at least 15 minutes before the start of surgery. Another 1000mg dose of IV acetaminophen will be administered 4 hours after the first dose. A rescue analgesic containing oxycodone will also be provided (with APAP concentrations of 325 mg per Hospital and FDA recommendations). IV Acetaminophen: 1000mg IV acetaminophen over 15 minutes every 4 hours for up to 2 doses.
31
Control
The control group (Placebo) will receive 100 mL of 0.9% normal saline in place of IV acetaminophen in the same manner as the experimental group; the investigator/physician in question will be blinded to the agent that is being administered. Patients will be discharged with instruction to continue APAP 500 mg PO every 6-8 hours. A rescue analgesic containing oxycodone will also be provided (with APAP concentrations of 325 mg per Hospital and FDA recommendations). Placebo: 100 mL of 0.9% normal saline over 15 minutes in place of IV acetaminophen.
31
Total62

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall Studypretreatment medical and billing reasons02

Baseline characteristics

CharacteristicIV AcetaminophenControlTotal
Age, Continuous53.7 years
STANDARD_DEVIATION 14.6
54.2 years
STANDARD_DEVIATION 14.4
53.95 years
STANDARD_DEVIATION 14.5
Region of Enrollment
United States
31 participants31 participants62 participants
Sex: Female, Male
Female
9 Participants17 Participants26 Participants
Sex: Female, Male
Male
22 Participants14 Participants36 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
13 / 3110 / 29
serious
Total, serious adverse events
0 / 310 / 29

Outcome results

Primary

Pain Level Assessed Using a Visual Analogue Scale (VAS) Scale

VAS is a validated, self-reported data sheet assessing average pain intensity. Possible scores range from 0 (no pain) to 10 (highest level of pain).

Time frame: 15 minutes and 120 minutes Post-Operatively

Population: At the 15 minute time point, data was obtained for 24 participants in the acetaminophen group and 26 participants in the control group. For the 120 minute time point, data was obtained for 7 participants in the acetaminophen group and 11 participants in the control group.

ArmMeasureGroupValue (MEDIAN)
IV AcetaminophenPain Level Assessed Using a Visual Analogue Scale (VAS) Scale15 minutes (n=24, 26)0 units on a scale
IV AcetaminophenPain Level Assessed Using a Visual Analogue Scale (VAS) Scale120 minutes (n=7, 11)0 units on a scale
ControlPain Level Assessed Using a Visual Analogue Scale (VAS) Scale15 minutes (n=24, 26)0 units on a scale
ControlPain Level Assessed Using a Visual Analogue Scale (VAS) Scale120 minutes (n=7, 11)2 units on a scale
Secondary

Number of Participants Who Experienced Postoperative Morbidity (Nausea)

Post-operative nausea will be monitored and measured through direct observation and nursing clinical record

Time frame: During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)

ArmMeasureValue (NUMBER)
IV AcetaminophenNumber of Participants Who Experienced Postoperative Morbidity (Nausea)13 participants
ControlNumber of Participants Who Experienced Postoperative Morbidity (Nausea)10 participants
Secondary

Number of Participants Who Received Intraoperative Supplemental Fentanyl

Number of participants who received intraoperative supplemental fentanyl. The decision to administer fentanyl is based on hemodynamic changes, such as increasing blood pressure and heart rate.

Time frame: During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)

ArmMeasureValue (NUMBER)
IV AcetaminophenNumber of Participants Who Received Intraoperative Supplemental Fentanyl9 participants
ControlNumber of Participants Who Received Intraoperative Supplemental Fentanyl4 participants
Secondary

Postoperative Vital Sign (Diastolic Blood Pressure)

Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery.

Time frame: During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)

ArmMeasureValue (MEAN)Dispersion
IV AcetaminophenPostoperative Vital Sign (Diastolic Blood Pressure)75 mmHgStandard Deviation 13.5
ControlPostoperative Vital Sign (Diastolic Blood Pressure)78.3 mmHgStandard Deviation 10.5
Secondary

Postoperative Vital Sign (Pulse)

Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery.

Time frame: During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)

ArmMeasureValue (MEAN)Dispersion
IV AcetaminophenPostoperative Vital Sign (Pulse)76.3 beats per minuteStandard Deviation 12.4
ControlPostoperative Vital Sign (Pulse)80 beats per minuteStandard Deviation 13.2
Secondary

Postoperative Vital Sign (Respiratory Rate)

Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery.

Time frame: During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)

ArmMeasureValue (MEAN)Dispersion
IV AcetaminophenPostoperative Vital Sign (Respiratory Rate)17.4 breaths per minuteStandard Deviation 1.2
ControlPostoperative Vital Sign (Respiratory Rate)17.2 breaths per minuteStandard Deviation 1.3
Secondary

Postoperative Vital Sign (Systolic Blood Pressure)

Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery.

Time frame: During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)

ArmMeasureValue (MEAN)Dispersion
IV AcetaminophenPostoperative Vital Sign (Systolic Blood Pressure)133 mmHgStandard Deviation 17.2
ControlPostoperative Vital Sign (Systolic Blood Pressure)144 mmHgStandard Deviation 15
Secondary

Postoperative Vital Sign (Temperature)

Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery.

Time frame: During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)

ArmMeasureValue (MEAN)Dispersion
IV AcetaminophenPostoperative Vital Sign (Temperature)97.1 FahrenheitStandard Deviation 0.8
ControlPostoperative Vital Sign (Temperature)97.4 FahrenheitStandard Deviation 0.8
Secondary

Total Doses of Postoperative Opiate (Morphine) Use

The total amount of morphine utilized in Postoperative Acute Care Unit (PACU) will be recorded. One dose is a 1mg bolus of morphine.

Time frame: During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)

ArmMeasureValue (MEDIAN)
IV AcetaminophenTotal Doses of Postoperative Opiate (Morphine) Use1.5 doses
ControlTotal Doses of Postoperative Opiate (Morphine) Use2.5 doses

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026